ArticleNAR genomics and bioinformatics2020
Development of multiepitope subunit protein vaccines against
Article in NAR genomics and bioinformatics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Rpf-Toxo: A Preliminary Computationally Designed Dense Granule Antigen-Based Multi-Epitope Vaccine Against Toxoplasma gondii.Veterinary medicine and science · 2026Article
- An Immunoinformatic Approach for a Multi-Epitope Vaccine Against Toxoplasma gondii.Parasite immunology · 2026Article
- Multi-Epitope-Based Peptide Vaccine Against Bovine Parainfluenza Virus Type 3: Design and Immunoinformatics Approach.Veterinary sciences · 2025Article
- Immunoinformatics-Based Multi-Epitope Vaccine Design AgainstHealth science reports · 2025Article
- Toxoplasma gondii C2 Domain Protein Deletion Mutant as a Promising Vaccine Against Toxoplasmosis in Mice.Microbial biotechnology · 2025Article
- Designing of an innovative conserved multiepitope subunit vaccine targeting SARS-CoV-2 glycoprotein and nucleoprotein through immunoinformatic.Scientific reports · 2025Article
- Screening of novel therapeutic targets and chimeric vaccine construction against antibiotic-resistantFrontiers in immunology · 2025Article
- In silico design of a multi-epitope vaccine against Cryptosporidium parvum using structural and immunoinformatics approaches.PloS one · 2025Article
- MIC13 ofJournal of parasitology research · 2025Article
- In Silico Subtractive Proteome Analysis to Design Multi-Epitope-Based Subunit Vaccine againstJournal of microbiology and biotechnology · 2024Article
- Genome-level therapeutic targets identification and chimeric Vaccine designing against theHeliyon · 2024Article
- TgVax452, an epitope-based candidate vaccine targeting Toxoplasma gondii tachyzoite-specific SAG1-related sequence (SRS) proteins: immunoinformatics, structural simulations and experimental evidence-based approaches.BMC infectious diseases · 2024Article
- PredictingIn silico pharmacology · 2024Article
- Proteomics Applications inPathogens (Basel, Switzerland) · 2023Review
- In Silico Design of a New Epitope-Based Vaccine against Grass Group 1 Allergens.Advances in respiratory medicine · 2023Article
- Article
- Article
- Toxoplasmosis vaccines: what we have and where to go?NPJ vaccines · 2022Review
- Immunoinformatics Studies and Design of a Potential Multi-Epitope Peptide Vaccine to Combat the Fatal Visceral Leishmaniasis.Vaccines · 2022Article
- Development of synthetic antigen vaccines for COVID-19.Human vaccines & immunotherapeutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately one-third of the world's human population is estimated to have been exposed to the parasite
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.